The businesss goals for this analysis had been to assess AZX100 ongoing protection.

The business’s goals for this analysis had been to assess AZX100 ongoing protection, to evaluate the standard of the clinical trial dataset to be able to guide future studies and to determine whether continuation of the trial will be futile from a statistical perspective nootropics . Steer, MD, PhD, President of Capstone Therapeutics. The two ongoing AZX100 Stage 2 keloid medical trials (OL-ASCAR-04, dosing 3.0mg and 10.0mg per linear cm – continuation announced March 2, 2010; and OL-ASCAR-05, dosing 0.3mg and 1. This article was reprinted from kaiserhealthnews.org with permission from the Henry J.